

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

NCT06667453

Status	RECRUITING
Phase	Phase 2
Sponsor	PepGen Inc
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (4)

- Confirmed diagnosis of DM1, as defined as having a repeat sequence in the DMPK gene with at least 100 CTG repeats
- Medical Research Council (MRC) score of e Grade 4- in bilateral tibialis anterior (TA) muscles (the ability to move through full range of motion and hold against at least moderate pressure from the examiner)
- Presence of myotonia
- Body Mass Index (BMI) of $\leq 32.0 \text{ kg/m}^2$

Exclusion (6)

- Congenital DM1
- Known history or presence of any clinically significant conditions that may interfere with study safety assessments
- Abnormal laboratory tests at screening considered clinically significant by the Investigator
- Medications specific for the treatment of myotonia within 2 weeks prior to screening
- Percent predicted forced vital capacity (FVC) $\leq 40\%$

... and 1 more (see full listing online)

Locations (8 total)

University of Calgary, Calgary, Alberta, Canada
Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada
CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada
... and 5 more locations